Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PMVP
Strong SellSinkerPMV Pharmaceuticals, Inc. · Healthcare · United States · $65M · Avg Vol: $879K/d
19
StockRankGet insider-trade alerts
Q
28
V
34
M
40
P/E (TTM)
—
ROE
-70.9%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 5.0M | — |
| EPS | -1.61 | -1.44 | -1.14 | -1.48 | — | -1.42 | -1.28 | -0.97 | — |
| Shares | 45.8M | 51.4M | 51.9M | 53.3M | +16.5% | 53.5M | — | — | — |
| Debt | 14.0M | 13.3M | 1.2M | 0.8M | -60.9% | 0.2M | — | — | — |
| Equity | 246.0M | 225.7M | 176.1M | 104.7M | -24.8% | — | — | — | — |
| Op CF | -63.8M | -55.7M | -51.3M | -73.6M | — | -71.3M | — | — | — |
| Inv CF | -1.4M | -50.5M | 53.4M | 70.2M | — | — | — | — | — |
| Fin CF | 1.0M | 35.6M | 0.3M | 0.5M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+27.4%
SMA 50SMA 200
Close
$1.44
RSI (14)
64.3
52W High
$1.88
From 52W High
0.8%
SCORE BREAKDOWN
Quality
28
ROIC
-79.6%9.4
ROE
-70.9%13.8
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-63.1%4.8
Piotroski
29.5
Int. Cover
—N/A
D/E Ratio
0.00x90.9
Current Ratio
7.70x82.8
Value
34
P/E (TTM)
—N/A
EV/EBITDA
0.1x25.0
P/FCF
—N/A
P/B
1.0x86.5
P/S
—N/A
Div Yield
—N/A
Momentum
40
52W High %
77%63.2
RS 6M
-23%37.5
SMA 50/200
0.99x53.7
EPS Rev 4W
-4.7%14.0
EPS Rev 12W
—N/A
EPS Improve
+19%33.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$65M
P/E (Forward)
-1.1x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PMVP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals, Inc.(you) | $65M | 19 | Strong Sell |
| 4875.T | MediciNova, Inc. | $70M | 18 | Strong Sell |
| NTRB | Nutriband Inc. | $54M | 19 | Strong Sell |
| NRXS | NeurAxis, Inc. | $75M | 18 | Strong Sell |
| LONA | LeonaBio, Inc. | $75M | 18 | Strong Sell |
| IMA | ImageneBio, Inc. | $61M | 15 | Strong Sell |
| HYFT | MindWalk Holdings Corp. | $65M | 14 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 14 | Strong Sell |
| INKT | MiNK Therapeutics, Inc. | $58M | 15 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 15 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%